See more : Héroux-Devtek Inc. (HERXF) Income Statement Analysis – Financial Results
Complete financial analysis of Aytu BioPharma, Inc. (AYTU) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aytu BioPharma, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Bertrandt Aktiengesellschaft (BDT.SW) Income Statement Analysis – Financial Results
- Digital Realty Trust, Inc. (DLR-PJ) Income Statement Analysis – Financial Results
- Kakao Pay Corp. (377300.KS) Income Statement Analysis – Financial Results
- Mangalam Cement Limited (MANGLMCEM.NS) Income Statement Analysis – Financial Results
- Gabriel India Limited (GABRIEL.BO) Income Statement Analysis – Financial Results
Aytu BioPharma, Inc. (AYTU)
About Aytu BioPharma, Inc.
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 81.00M | 107.40M | 96.67M | 65.63M | 27.63M | 7.32M | 3.66M | 3.22M | 2.56M | 261.78K | 58.93K | 1.75K | 1.75K | 0.00 | 0.00 | 1.75K | 0.00 | 0.00 |
| Cost of Revenue | 26.42M | 40.77M | 44.39M | 36.43M | 7.55M | 2.20M | 2.05M | 1.42M | 957.08K | 88.11K | 0.00 | -48.25K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 54.59M | 66.63M | 52.28M | 29.20M | 20.08M | 5.12M | 1.61M | 1.80M | 1.61M | 173.67K | 58.93K | 50.00K | 1.75K | 0.00 | 0.00 | 1.75K | 0.00 | 0.00 |
| Gross Profit Ratio | 67.39% | 62.04% | 54.08% | 44.49% | 72.67% | 69.92% | 43.97% | 56.00% | 62.65% | 66.34% | 100.00% | 2,857.14% | 100.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 2.79M | 4.10M | 14.44M | 5.62M | 1.72M | 589.07K | 167.60K | 1.35M | 6.32M | 3.42M | 4.06M | 2.76M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 22.51M | 28.63M | 31.17M | 25.50M | 19.66M | 0.00 | 17.73M | 17.61M | 8.83M | 4.38M | 2.35M | 47.98K | 58.11K | 129.37K | 54.16K | 54.86K | 54.98K | 0.00 |
| Selling & Marketing | 26.96M | 41.45M | 38.71M | 30.31M | 11.40M | 0.00 | 0.00 | -242.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 49.47M | 70.08M | 69.88M | 55.81M | 34.80M | 19.24M | 17.73M | 17.61M | 8.83M | 4.38M | 2.35M | 47.98K | 58.11K | 129.37K | 54.16K | 54.86K | 54.98K | 46.89K |
| Other Expenses | 7.58M | -4.78M | 4.07M | 6.01M | 4.49M | 2.14M | 6.28M | 1.71M | 664.71K | 4.89K | 6.18K | 6.18K | 7.34K | 4.25K | 2.58K | 2.71K | 0.00 | 0.00 |
| Operating Expenses | 60.57M | 78.96M | 88.39M | 67.44M | 41.01M | 21.96M | 19.45M | 20.66M | 15.81M | 7.81M | 6.41M | 54.16K | 58.11K | 133.62K | 56.74K | 57.57K | 54.98K | 46.89K |
| Cost & Expenses | 86.26M | 119.73M | 132.77M | 103.87M | 48.57M | 24.17M | 21.50M | 22.08M | 16.77M | 7.89M | 6.41M | 54.16K | 58.11K | 133.62K | 56.74K | 57.57K | 54.98K | 46.89K |
| Interest Income | 0.00 | 9.00K | 14.00K | 6.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 4.79M | 0.00 | 147.50M | 0.00 | 0.00 | 0.00 | 749.42K | 2.53M | 5.49M | 114.99K | 45.55K | 4.90K | 3.32K | 3.18K | 3.80K | 3.07K | 0.00 | 2.06K |
| Depreciation & Amortization | 8.27M | 8.82M | 10.15M | 7.70M | 4.59M | 2.24M | 1.85M | 1.84M | 874.79K | 118.20K | 97.48K | 4.94K | 6.15K | 6.76K | 9.19K | 8.28K | 7.52K | 6.42K |
| EBITDA | -1.01M | -3.51M | -27.96M | -29.04M | -12.21M | -14.12M | -15.25M | -18.13M | -21.81M | -7.51M | -52.71K | -47.47K | -50.21K | -126.86K | -47.28K | -47.54K | -47.47K | -40.47K |
| EBITDA Ratio | -1.25% | -7.07% | 42.70% | -22.08% | -89.07% | -59.69% | -245.22% | -449.95% | -520.19% | -2,870.37% | -10,604.89% | -2,712.69% | -2,868.91% | 0.00% | 0.00% | -2,716.51% | 0.00% | 0.00% |
| Operating Income | -5.25M | -17.07M | 37.22M | -38.24M | -20.94M | -16.85M | -19.70M | -20.13M | -21.70M | -7.63M | -6.35M | -52.41K | -56.36K | -133.62K | -56.74K | -55.82K | -54.98K | -46.89K |
| Operating Income Ratio | -6.49% | -15.89% | 38.50% | -58.26% | -75.76% | -230.13% | -538.26% | -624.70% | -847.02% | -2,915.53% | -10,770.31% | -2,995.09% | -3,220.34% | 0.00% | 0.00% | -3,189.83% | 0.00% | 0.00% |
| Total Other Income/Expenses | -8.82M | 14.00K | 1.02M | 840.00K | 7.51M | -10.29M | 9.51M | -2.38M | -6.48M | -114.99K | -4.23K | -4.90K | -3.32K | -3.18K | -3.53K | -3.07K | -2.19K | -2.06K |
| Income Before Tax | -14.08M | -17.05M | -110.28M | -58.03M | -13.62M | -27.13M | -10.19M | -22.51M | -28.18M | -7.75M | -6.39M | -57.32K | -59.68K | -136.80K | -56.47K | -58.89K | -48.95K | -48.95K |
| Income Before Tax Ratio | -17.38% | -15.88% | -114.08% | -88.42% | -49.29% | -370.64% | -278.36% | -698.67% | -1,099.73% | -2,959.45% | -10,847.61% | -3,275.31% | -3,410.00% | 0.00% | 0.00% | -3,365.37% | 0.00% | 0.00% |
| Income Tax Expense | 1.77M | -57.00K | -110.00K | 259.00K | -9.92M | 20.04M | -2.13M | 1.11M | 8.48M | -23.91K | -813.70K | 911.31K | 3.32K | 3.18K | -548.00 | 3.07K | 2.19K | 2.06K |
| Net Income | -15.84M | -17.05M | -108.78M | -58.29M | -13.62M | -47.17M | -10.19M | -22.51M | -28.18M | -7.72M | -5.58M | -57.32K | -59.68K | -136.80K | -60.27K | -58.89K | -57.17K | -48.95K |
| Net Income Ratio | -19.56% | -15.88% | -113.97% | -88.81% | -13.39% | -644.33% | -278.36% | -698.67% | -1,099.73% | -2,950.32% | -9,466.80% | -3,275.31% | -3,410.00% | 0.00% | 0.00% | -3,365.37% | 0.00% | 0.00% |
| EPS | -2.86 | -5.11 | -74.01 | -69.60 | -60.20 | -1.21K | -3.06K | -193.19K | -1.29M | -551.67K | -619.85K | -7.16K | -7.46K | -17.10K | -10.05K | -11.78K | -11.43K | -48.95K |
| EPS Diluted | -2.86 | -5.11 | -74.01 | -69.60 | -60.20 | -1.21K | -3.06K | -193.19K | -1.29M | -551.67K | -619.85K | -7.16K | -7.46K | -17.10K | -10.05K | -11.78K | -11.43K | -48.95K |
| Weighted Avg Shares Out | 5.54M | 3.34M | 1.47M | 840.00K | 230.00K | 38.97K | 3.33K | 116.51 | 21.77 | 14.00 | 9.00 | 8.00 | 8.00 | 8.00 | 6.00 | 5.00 | 5.00 | 1.00 |
| Weighted Avg Shares Out (Dil) | 5.54M | 3.34M | 1.47M | 840.00K | 230.00K | 38.97K | 3.33K | 116.51 | 21.77 | 14.00 | 9.00 | 8.00 | 8.00 | 8.00 | 6.00 | 5.00 | 5.00 | 1.00 |
AYTU Stock Price Increases Over 15% Pre-Market: Why It Happened
The stock price of Aytu Bioscience Inc (NASDAQ: AYTU) increased by over 15% pre-market. This is why it happened.
Aytu BioScience Announces Positive Clinical Results from Healight(TM) Pilot Study in SARS-CoV-2 Patients
Data indicate endotracheal UVA light catheter therapy reduces SARS-CoV-2 viral load and improves clinical outcomes in mechanically ventilated SARS-CoV-2 patients ENGLEWOOD, CO / ACCESSWIRE / March 8, 2021 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing...
Aytu BioScience, Inc. (AYTU) CEO Joshua Disbrow on Q2 2021 Results - Earnings Call Transcript
Aytu BioScience, Inc. (AYTU) CEO Joshua Disbrow on Q2 2021 Results - Earnings Call Transcript
Play Stocks With Rising P/E to Realize Solid Gains
Bet on these top-ranked stocks with rising P/E to realize outsized gains.
Aytu BioScience: Time To Call In The Cavalry Of Value Catalysts
Long-term investors in Aytu BioScience have endured a series of value and confidence eroding actions by the company over the last 12 months including dilution and reverse splits. Aytu has significant upside potential and numerous exciting catalysts to be announced...
Why These 4 Health Care Stocks Are Moving Today
Osmotica Pharmaceuticals (NASDAQ: OSMT) shares were trading higher Monday in anticipation of a ruling by the FDA on the company's New Drug Application for Arbaclofen ER in patients with multiple sclerosis. Osmotica Pharmaceuticals is focused on developing, manufacturing and commercializing...
Aytu BioScience Announces Completion of Healight(TM) Safety Study in Critically Ill COVID-19 Patients
First Safety Study Utilizing Ultraviolet A Light Catheter as a Prospective Anti-Infective in Critically Ill, Intubated SARS-Cov-2 Patients ENGLEWOOD, CO / ACCESSWIRE / December 28, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company (the "Company") focused on commercializing...
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Neos Therapeutics, Inc.
NEW YORK, Dec. 10, 2020 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Neos Therapeutics, Inc. (NASDAQ: NEOS) and its board of directors concerning the proposed acquisition of the company by Aytu BioScience, Inc. (NASDAQ: AYTU)....
Merger Thursday: Gilead Buys German Drug Company, Aytu-Neos All-Stock Deal, Boehringer Picks Up NBE-Therapeutics
The day dawned as an M&A Thursday for the biotech sector, as a slew of deals of varied sizes were announced, with Gilead Sciences, Inc. (NASDAQ: GILD) and Aytu BioScience, Inc. (NASDAQ: AYTU) in the mix. Gilead Snaps Up Germany Drug Company...
Neos Therapeutics News: Why NEOS Stock Is Soaring Today
Neos Therapeutics (NEOS) news for Thursday concerning a merger with Aytu BioScience (AYTU) has shares of NEOS and AYTU stock on the rise. The post Neos Therapeutics News: Why NEOS Stock Is Soaring Today appeared first on InvestorPlace.
Source: https://incomestatements.info
Category: Stock Reports